Sharps Technology CEO, Robert Hayes, to Present at the Life Sciences Virtual Investor Forum on June 12 at 9:30AM ET
MWN-AI** Summary
Robert Hayes, CEO of Sharps Technology, will present at the Life Sciences Virtual Investor Forum on June 12, 2025, at 9:30 AM ET. This significant event, hosted by VirtualInvestorConferences.com, allows investors to engage with company leadership in real-time. Sharps Technology, listed on Nasdaq as “STSS” and “STSSW,” specializes in innovative medical devices and pharmaceutical packaging, notably their patented smart safety syringe products designed for the healthcare industry.
The timing of Hayes' presentation coincides with Sharps’ initial commercial deliveries under three customer orders, marking a critical shift for the company as it transitions into revenue-generating operations. These shipments are being facilitated from Sharps' upgraded manufacturing facility in Hungary, which now supports high-volume production. This milestone is a testament to Sharps’ strategic growth and commitment to providing advanced safety solutions in the medical field.
The Life Sciences Virtual Investor Forum aims to enhance investor access and provides a platform for real-time questions and engagement, offering a dynamic experience akin to onsite conferences. For those unable to attend live, an archived version of the presentation will be available afterward. Interested investors are encouraged to pre-register and conduct online system checks in advance.
Sharps Technology's focus on ultra-low waste capabilities with both passive and active safety features places it at the forefront of the smart safety syringe market. The company also integrates specialized copolymer technology aimed at the prefillable syringe segment. As Sharps Technology continues to make strides in the medical device sector, its upcoming presentation by CEO Robert Hayes is highly anticipated by investors keen to learn more about the company’s future prospects and innovations.
MWN-AI** Analysis
As Sharps Technology approaches its pivotal presentation at the Life Sciences Virtual Investor Forum on June 12, poised at 9:30 AM ET, investors should prepare for a critical evaluation of the company’s trajectory. Led by CEO Robert Hayes, this event marks an important milestone following the company’s announcement of its inaugural commercial shipments, indicating a transition to revenue-generating operations.
Investment analysts should pay close attention to Hayes' insights during this live presentation, particularly concerning the operational upgrades at Sharps' Hungary facility. Knowing that manufacturing capacity and efficiency are crucial for meeting burgeoning demand, Hayes may elaborate on how recent enhancements bolster their production capabilities. An emphasis on swift, efficient distribution can signal strong future revenue streams.
Additionally, investors should be mindful of the company’s patented smart safety syringe technology. With a mounting global emphasis on safety in medical procedures, Sharps’ innovative solutions align well with market demands. Those keen on medical device investments may find the company’s niche in ultra-low waste, incorporating both passive and active safety features, particularly compelling.
The interactive nature of the forum will offer real-time engagement opportunities, allowing investors to pose questions directly to management. This access could yield valuable insights into strategic objectives, competitive positioning, and regulatory challenges. Given that forward-looking statements accompany such discussions, participants should maintain a critical lens, recognizing the potential uncertainties inherent in the marketplace.
Overall, the upcoming presentation is a significant event for Sharps Technology and can serve as a barometer for investors keen on future growth potential. Staying attuned to Hayes' commentary and subsequent market reactions will be pivotal for informed investment decisions in the healthcare sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart safety syringe products to the healthcare industry, today announced that Robert Hayes, CEO, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on June 12 th , 2025 at 9:30 AM ET.
Sharps recently announced that the Company has commenced shipments under three customer orders tied to previously announced purchase agreements. These shipments represent the Company’s first commercial deliveries and its transition to revenue-generating operations. All products are being manufactured and shipped from Sharps’ facility in Hungary, which has undergone significant upgrades to support high-volume production. Read the update release HERE .
Presentation Access:
- Presenter: Robert Hayes, CEO
- DATE : June 12 th
- TIME : 9:30 AM ET
- LINK: HERE
- 1x1 Meeting Availability Contact: adam@holdsworthco.com
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com .
About Sharps Technology:
Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company’s product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary. For additional information, please visit www.sharpstechnology.com .
Investor Contact:
Holdsworth Partners
Adam Holdsworth
Phone: 917-497-9287
Email: IR@sharpstechnology.com
FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements”. Forward-looking statements reflect our current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” “poised” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
About Virtual Investor Conferences®
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.
Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.
Virtual Investor Conferences:
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com
FAQ**
How does the recent shipment of orders impact Sharps Technology Inc. Warrant STSSW in terms of potential revenue generation moving forward?
What strategies does Sharps Technology Inc. have in place to enhance the competitiveness of its products related to the Sharps Technology Inc. Warrant STSSW?
Can you elaborate on the implications of the manufacturing upgrades in Hungary for the growth and sustainability of Sharps Technology Inc. Warrant STSSW?
What are the key milestones that investors should look for in relation to Sharps Technology Inc. Warrant STSSW as the company transitions to revenue-generating operations?
**MWN-AI FAQ is based on asking OpenAI questions about Sharps Technology Inc. Warrant (NASDAQ: STSSW).
NASDAQ: STSSW
STSSW Trading
26.0% G/L:
$0.0315 Last:
4,589 Volume:
$0.0315 Open:
